These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27511999)

  • 1. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up.
    Wypasek E; Mazur P; Bochenek M; Awsiuk M; Grudzien G; Plicner A; Undas A
    J Physiol Pharmacol; 2016 Jun; 67(3):385-93. PubMed ID: 27511999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.
    Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A
    Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin.
    Praxedes MFS; Martins MAP; Mourão AOM; Gomes KB; Reis EA; Souza RP; Campos EIF; Ribeiro DD; Rocha MOC
    Eur J Clin Pharmacol; 2020 Feb; 76(2):199-209. PubMed ID: 31720756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
    Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
    J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic and clinical factors on warfarin therapy in patients early after heart valve replacement surgery.
    Li B; Liu R; Wang C; Ren C; Zhang S; Zhang F; Zhang J; Liu S; Wei Y; Liu W; Song B; Wu X
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1685-1693. PubMed ID: 31444512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study.
    Li Y; Yu J; Kuang Y; Wu C; Yang L; Fang Q; Pei Q; Yang G
    Curr Med Res Opin; 2020 Sep; 36(9):1433-1439. PubMed ID: 32677855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support.
    Awad M; Czer LS; Soliman C; Mirocha J; Ruzza A; Pinzas J; Rihbany K; Chang D; Moriguchi J; Ramzy D; Esmailian F; Kobashigawa J; Arabia F
    ASAIO J; 2015; 61(4):391-6. PubMed ID: 26125664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
    Helin TA; Joutsi-Korhonen L; Asmundela H; Niemi M; Orpana A; Lassila R
    Br J Clin Pharmacol; 2019 Aug; 85(8):1684-1691. PubMed ID: 30933373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals].
    Benavides F; Grossman N; Poggi H; Nieto E; Bertrán A; Araos D; Vásquez M; Ibarra I; Cáceres F; Espinoza K; Lagos M; Repetto M G
    Rev Med Chil; 2015 Nov; 143(11):1369-76. PubMed ID: 26757860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors.
    Bryk A; Wypasek E; Awsiuk M; Maj D; Undas A
    Cardiovasc Drugs Ther; 2015 Jun; 29(3):257-64. PubMed ID: 25986145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.
    Zhou L; Ding Y; Gao Y; Yang B; Bao J; Ma J
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):1-9. PubMed ID: 31914334
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic.
    Schapkaitz E; Sithole J
    J Vasc Nurs; 2017 Mar; 35(1):27-30. PubMed ID: 28224948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.